TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options Under Clinical Evaluation for Recurrent Ewing Sarcoma
Source: Ewing Sarcoma and Undifferentiated Small Round Cell Sarcomas of Bone and Soft Tissue Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 27, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Recurrent Ewing Sarcoma
Information about NCI-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Source links and citations
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
NCT04890093 (Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors): PEN-866 is a novel molecule consisting of SN-38 conjugated to a heat shock protein 90 (HSP90) inhibitor that has been shown to have a pharmacokinetic advantage over irinotecan in preclinical models. In preclinical models of Ewing sarcoma, PEN-866 had superior efficacy and pharmacodynamics compared with irinotecan. For the phase I portion of this trial, any patient aged 12 to 39 years with a relapsed or refractory solid tumor is eligible. The phase II portion of this trial will enroll only patients aged 12 to 39 years with relapsed or refractory Ewing sarcoma or rhabdomyosarcoma.
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Preserved source evidence · Not medical advice